Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
12,383 stopped studies mapped to Malignant Neoplasm and descendants · 89% state a reason
Over the 12,383 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05014139 | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle… | Phase 1 | terminated | Aug 20, 2021 | Astellas Pharma Global Development, Inc. | Trial was discontinued for strategic reasons. Decision was not based on safety concerns, futility,… | Safety / toxicity |
| NCT05403723 | Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC | Phase 1 | suspended | Jun 3, 2022 | University of Maryland, Baltimore | PI changed institution. Not yet approved at current location. | Other (stated, no rule matched) |
| NCT06722807 | ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses(CASPIAN) | N/A | suspended | Dec 9, 2024 | University of Florida | Interim analysis | Efficacy / futility |
| NCT07313592 | Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients | — | suspended | Jan 2, 2026 | Washington University School of Medicine | Admin review | Other (stated, no rule matched) |
| NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular…(CLeAR) | Phase 1 | withdrawn | Jan 26, 2026 | Virginia Commonwealth University | The study was withdrawn because the pharmaceutical company decided not to pursue this combination… | Sponsor / business decision |
| NCT07644702 | WE-CARE Community Health Forums to Increase Breast Cancer Screening and Clinical Trial… | N/A | terminated | Jun 12, 2026 | Mayo Clinic | Unable to reach enrollment target before the forum date of 9/17/2026 | Enrollment / accrual |
| NCT01039922 | SwissNET - a Registry for Neuroendocrine Tumours in Switzerland(SwissNET) | — | terminated | Dec 25, 2009 | Insel Gruppe AG, University Hospital Bern | The register will no longer be maintained on a prospective basis | Other (stated, no rule matched) |
| NCT03694483 | Prostasomes as Diagnostic Tool for Prostate Cancer Detection | — | suspended | Oct 3, 2018 | Hackensack Meridian Health | Staffing changes, pending funding renewal | Funding |
| NCT04579523 | ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and… | Phase 1 | withdrawn | Oct 8, 2020 | Fred Hutchinson Cancer Center | Study withdrawn before opening to accrual. | Enrollment / accrual |
| NCT04866810 | The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN) | N/A | suspended | Apr 30, 2021 | National Cancer Institute (NCI) | On hold pending planned interim analysis. | Efficacy / futility |
| NCT05226598 | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With… | Phase 3 | terminated | Feb 7, 2022 | Merck Sharp & Dohme LLC | MK-7684A-007 was terminated early due to futility. A non-submission CSR, not intended to support… | Efficacy / futility |
| NCT05648461 | Phase II Study Exploring Five Fractions of Post-operative Radiation Therapy in Head and…(Accelerate) | N/A | withdrawn | Dec 13, 2022 | All India Institute of Medical Sciences | concern of extreme hypofractionation, toxicity. It is decided to go in a stepwise manner and first… | Safety / toxicity |
| NCT06134245 | HOme USability Evaluation(HOUSE) | — | withdrawn | Nov 18, 2023 | Entia Ltd | Change in trial pipeline. Study no longer required. | Other (stated, no rule matched) |
| NCT06544070 | Capillary Blood Accuracy(CAPYBARA) | — | withdrawn | Aug 9, 2024 | Entia Ltd | Change in trial pipeline. Study no longer required. | Other (stated, no rule matched) |
| NCT06597734 | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in… | Phase 2 | withdrawn | Sep 19, 2024 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT06639607 | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and…(PRiME II) | Phase 1 / Phase 2 | suspended | Oct 15, 2024 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT06868238 | Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel… | Phase 2 | suspended | Mar 10, 2025 | University of Florida | Major protocol revision involving eligibility criteria and screening procedures in progress | Other (stated, no rule matched) |
| NCT07098364 | ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in… | Phase 1 / Phase 2 | suspended | Aug 1, 2025 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Phase 1 | suspended | Sep 18, 2025 | Chongqing Precision Biotech Co., Ltd | Sponsor stopped the study. | Other (stated, no rule matched) |
| NCT07720115 | Phase 2 Trial Of S-531011 With RadScopal In Previously Treated Metastatic Colorectal… | Phase 2 | withdrawn | Jul 22, 2026 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT01029873 | QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma | Phase 1 / Phase 2 | terminated | Dec 10, 2009 | Altor BioScience | Sponsor decision | Sponsor / business decision |
| NCT04251533 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With…(EPIK-B3) | Phase 3 | terminated | Feb 5, 2020 | Novartis Pharmaceuticals | The study was terminated following a strategic decision to halt recruitment due to persistently… | Safety / toxicity |
| NCT04683653 | Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer | Phase 1 / Phase 2 | suspended | Dec 24, 2020 | University of Chicago | Enrollment Goal Met | Enrollment / accrual |
| NCT04993391 | AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Aug 6, 2021 | Suzhou Junjing BioSciences Co., Ltd. | The study was stopped because of a change in the study strategy | Sponsor / business decision |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for…(FORTITUDE-102) | Phase 3 | terminated | Nov 8, 2021 | Amgen | Study was terminated by sponsor | Other (stated, no rule matched) |
| NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for… | Phase 3 | terminated | Dec 27, 2022 | Merck Sharp & Dohme LLC | Business Reason | Sponsor / business decision |
| NCT06014827 | Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy… | Phase 2 | suspended | Aug 28, 2023 | City of Hope Medical Center | Budget Issue | Funding |
| NCT06549478 | Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases | Phase 1 | suspended | Aug 12, 2024 | City of Hope Medical Center | Budget Issue | Funding |
| NCT06572605 | External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of… | Phase 1 / Phase 2 | suspended | Aug 27, 2024 | City of Hope Medical Center | pending amendment | Other (stated, no rule matched) |
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | Phase 2 | suspended | Nov 8, 2024 | Leland Metheny | insufficient funding | Funding |
| NCT06704152 | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant… | Phase 1 / Phase 2 | terminated | Nov 25, 2024 | BlueSphere Bio, Inc | Company Decision | Sponsor / business decision |
| NCT07566585 | Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute… | Phase 1 | withdrawn | May 5, 2026 | BlueSphere Bio, Inc | Company Decision | Sponsor / business decision |
| NCT04947618 | Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From…(DVR-Lym-Nim) | — | terminated | Jul 1, 2021 | Centre Hospitalier Universitaire de Nīmes | The doctor retired and there's no one to take over the project | Other (stated, no rule matched) |
| NCT05685602 | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic… | Phase 1 | suspended | Jan 17, 2023 | National Cancer Institute (NCI) | Drug Supply Issues | Drug supply |
| NCT06329570 | Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment… | Phase 1 / Phase 2 | suspended | Mar 26, 2024 | NaviFUS Corporation | FDA reviewing | Other (stated, no rule matched) |
| NCT06573294 | Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors | Phase 1 | terminated | Aug 27, 2024 | Genmab | Genmab has decided to terminate the GEN1057 program due to marginal anti-tumor activity not… | Other (stated, no rule matched) |
| NCT06888323 | Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients… | Phase 1 | suspended | Mar 21, 2025 | National Cancer Institute (NCI) | Drug Supply Issues | Drug supply |
| NCT02129699 | Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy(SPLENDOUR) | Phase 3 | terminated | May 2, 2014 | ETOP IBCSG Partners Foundation | Completion of recruitment was not feasible as accrual was slower than anticipated. Even if a… | Enrollment / accrual |
| NCT03952598 | Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of… | Phase 2 | suspended | May 16, 2019 | National Cancer Institute (NCI) | Study on hold pending possible updates with the team. | Other (stated, no rule matched) |
| NCT04544735 | Improving Women's Function After Pelvic Radiation | N/A | suspended | Sep 10, 2020 | Duke University | Study is suspended due to lack of funds. Will resume as soon as funding is secured. | Funding |
| NCT04926662 | Understanding Rural Patient and Provide Preferences for Mobile Lung Cancer Screening… | — | suspended | Jun 15, 2021 | Dartmouth-Hitchcock Medical Center | Study is paused while pre-aim 1 work is being done | Other (stated, no rule matched) |
| NCT04315233 | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent…(CHARGE) | Phase 1 | terminated | Mar 19, 2020 | University of Utah | No accrual in one year | Enrollment / accrual |
| NCT05275868 | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer | Phase 1 | terminated | Mar 11, 2022 | Novartis Pharmaceuticals | The trial was terminated due to a business decision and not as a result of any safety concerns | Safety / toxicity |
| NCT06050252 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine… | Phase 2 | suspended | Sep 22, 2023 | National Cancer Institute (NCI) | Other - evaluation of patients on first stage | Other (stated, no rule matched) |
| NCT06968988 | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic… | Phase 1 | suspended | May 13, 2025 | Washington University School of Medicine | Protocol amendment | Other (stated, no rule matched) |
| NCT03145857 | A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors… | Phase 1 / Phase 2 | terminated | May 9, 2017 | AHS Cancer Control Alberta | The market approved 68Ga-DOTATATE (NETSPOT(R)) is now approved for public funding in Alberta and is… | Drug supply |
| NCT04246177 | Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in… | Phase 3 | terminated | Jan 29, 2020 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT05813327 | Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma | Phase 1 | terminated | Apr 14, 2023 | Washington University School of Medicine | Polaris decided to close to accrual. | Enrollment / accrual |
| NCT06232044 | Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With… | Phase 1 / Phase 2 | suspended | Jan 30, 2024 | Alliance for Clinical Trials in Oncology | Enrollment to Dose Level 1 cohort has been met | Enrollment / accrual |
| NCT06405230 | Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular… | Phase 1 / Phase 2 | terminated | May 8, 2024 | GlaxoSmithKline | Operational challenges | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials